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This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: Appleton R,
Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status
epilepticus in children. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD001905. DOI:
10.1002/14651858.CD001905.pub2.
Further information for this Cochrane review is available in this issue of EBCH in the accompanying Summary
article.
Commentary by David McGillivray, Peter
Dayan and Martin Pusic
The treatment of an acute convulsion can be a life-
saving intervention, especially in cases where the con-
vulsion is likely to be prolonged or leaves the patient
susceptible to aspiration or permanent neurologic dam-
age (1). There is wide practice variation in the medica-
tions used to abort persistent tonic-clonic convulsions
(we leave aside the treatment of partial complex status
epilepticus).
The ambitious Cochrane review completed by
Appleton et al. starts out by stating that ‘benzo-
diazepines (midazolam, diazepam, lorazepam), phe-
nobarbitone, phenytoin and paraldehyde may all be
regarded as drugs of first choice in the management
of acute tonic-clonic convulsions in children’ (2).
The task is then to determine which medication and
route of administration leads to seizure cessation most
rapidly without adverse side effects. The question is
complicated given that six medications are considered
along with multiple routes of administration that can
change the pharmacokinetics of the medication. Fur-
ther complicating study design is that fact that seizures
with different clinical features may respond differently
to medications. An investigator must consider whether
to include patients with a narrow spectrum of seizure
etiologies (e.g. febrile seizures) as opposed to includ-
ing ‘all-comers’. Additionally, efficacy and adverse
event outcomes are not well standardized.
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The Appleton review assessed clinical trials in
which different drug treatments for acute tonic-clonic
convulsions in children were compared. They specifi-
cally excluded neonatal seizures but did not distinguish
between seizure etiologies or aspects of prior seizure
history, including whether the seizure was a first pre-
sentation or the latest of ongoing refractory seizures.
The review is an update of an earlier Cochrane review
carried out by the same group in 2002 (2). At that
time, the only study identified was their own 102
patient quasi-randomized trial comparing lorazepam
and diazepam. In the present update, they also include
three recent studies, all randomized trials. This brings
the total number of patients in the review up to 483, a
relatively small number considering the frequency of
this presentation.
The review has much to recommend it. The authors
developed a review protocol a priori that defined well
the types of participants, interventions and outcome
measures they would include. The search was compre-
hensive and two investigators independently decided
on which studies to include of the six their search iden-
tified. They do not report whether the two investiga-
tors agreed on all studies to include but they resolved
any disagreements by discussion. While no quantita-
tive validity criteria were used, the risks of bias are
described for each trial including the type of random-
ization and blinding.
The authors found that: (a) lorazepam was more
effective than diazepam both intravenously and rec-
tally for stopping seizures (total n = 86 patients)
and the use of lorazepam resulted in less respiratory
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depression; (b) mucosal (intranasal or buccal) midazo-
lam was as effective as intravenous diazepam [again,
small number (52 seizure episodes) in the analysis]
and is possibly more effective than rectal diazepam
(n = 219 seizure episodes); and (c) that intranasal
lorazepam is more effective than intramuscular par-
aldehyde (n = 160 seizure episodes). In comparing
the medications, the main outcome used was ‘seizure
cessation’.
The Appleton review did not include several poten-
tially noteworthy studies. Chamberlain et al. compared
intramuscular midazolam with intravenous diazepam
for treatment of ‘motor’ seizures lasting more than
10 min, with their main outcome variable being time
to seizure cessation (3). They found that clinicians
could administer the midazolam more quickly, which
likely accounted for a decreased time to seizure ces-
sation (7.8 min vs 11.2 min for diazepam). This study
was excluded as it could not be determined if seizures
were tonic, clonic, myoclonic or tonic-clonic. A ran-
domized controlled trial by Shah et al. found similar
results when they compared the same medications and
routes (4). In a study of African patients published
after the Cochrane update, Mpimbaza et al. random-
ized 330 patients to receive either rectal diazepam
or buccal midazolam to patients who had convulsed
for more than 5 min. Importantly, two-thirds of the
patients had positive malaria smears (5). They found
that buccal midazolam was appreciably more effec-
tive at stopping the seizure within 10 min in both the
patients with and without malaria. As the optimal med-
ication and route of administration remains uncertain,
it is encouraging that investigators continue to conduct
randomized trials that compare medications and routes
of administration for the treatment of convulsions in
children.
Most physicians use a benzodiazepine as their first
line agent for tonic-clonic seizures. The Appleton
review and others indicates that there is reasonable
but not definitive evidence from randomized trials
that lorazepam is preferred ahead of diazepam when
the intravenous route is used (2,6). This question
will be more definitively addressed by the PECARN
research network in the US which is conducting a large
randomized controlled trial comparing intravenous
lorazepam with diazepam. In those individuals in
whom intravenous access is not available, buccal
or intramuscular midazolam are likely the preferred
choices (Appleton, Prasad). The Appleton review
points out that randomized controlled trials directly
comparing intravenous lorazepam to midazolam are
not available. However, the comparisons that are
available do suggest that we can begin to simplify and
standardize our approach to the acutely seizing child.
Ideally, the clinician could choose a single ben-
zodiazepine to be used as a first line agent whether
or not an IV is available. Given the relative hetero-
geneity of the research evidence, it is not surprising
that review articles suggest several different possi-
bilities for the initial treatment of status epilepticus.
Standardization and simplicity of seizure protocols are
important to allow for rapid treatment, avoidance of
medication errors, ease of education of staff (nurses,
pharmacists, physicians), and an in-depth familiarity
of particular agents. Standardization also facilitates the
cohesiveness of the treatment teams, including those in
the EMS system, emergency department, and inpatient
settings.
Midazalom may become the single agent of choice
as it appears to both effectively stop seizures via
several routes (intranasal, buccal, intravenous, and
intramuscular) and does not have a worse adverse
event profile compared to other agents (7,8). Definitive
data do not exist, however, comparing midazolam to
all other medications via all routes (e.g. intravenous
lorazepam has not been compared to intravenous
midazolam). The use of midazolam as a single agent
has been considered by others (7,9). Brevoord et al.
have previously suggested a simplified protocol for
status epilepticus based on the use of midazolam and
phenytoin (9).
Midazolam has other features that make it an excel-
lent first line choice for status epilepticus. It is a med-
ication that is very familiar to emergency medicine
physicians, intensivists and anesthesiologists for use
in procedural sedation, rapid sequence intubation,
and status epilepticus. Intravenous midazolam infusion
has been shown to be effective in the most worri-
some patients, those with refractory status epilepticus
unresponsive to the usual anticonvulsants (diazepam,
lorazepam, phenytoin, and phenobarbital) (8,10–13).
Midazolam as a single dose, or as an infusion, is
able to stop refractory status epilepticus effectively
(8,10–13). If midazolam is proposed as the medica-
tion to use after all others have failed, it would seem
logical that it could be a good choice as a first line
agent as long as there are no adverse side effects to
its use.
In seizing patients without an intravenous at the
time of presentation, the Appleton review and other
studies support the choice of intranasal, buccal or intra-
muscular midazolam in terms of rapidity of seizure
cessation. For patients with intravenous access, the
current choice would appear to be lorazepam based
on the available evidence though we have made an
argument that midazolam could be chosen for this
indication as well. We agree with the Appleton group
that more research is required, with perhaps the most
urgent comparison being between intravenous mida-
zolam and intravenous lorazepam in order to confirm
that midazolam should be the single agent of choice
by any route. In future studies the goal of stream-
lining the treatment of tonic-clonic convulsions and
status epilepticus, ideally with a single first line agent,
should be a guiding principle.
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Response from the Review Authors
We appreciate the opportunity to respond to the Com-
mentary on our Cochrane review published in 2008.
We consider that this commentary provides a largely
accurate interpretation of the Review although we
would question the comment that ‘several’ noteworthy
studies were not included, as in fact this was limited
to only two [Chamberlain (1997) and Shah (2005)].
We would agree that any protocol or algorithm could
(and should) be simplified if this were possible, and
specifically to assess the role and use of midazolam as
the preferred benzodiazepine primarily because of its
multiple routes of administration and well-known (and
accepted), effectiveness and safety profiles. However,
lorazepam could also be considered as the preferred
benzodiazepine based on the evidence of its effective-
ness and safety using the intravenous, buccal and nasal
routes of administration.
It would also be interesting, if not appropriate, to
consider a randomized clinical trial (RCT) of intra-
venous phenytoin vs levetiracetam for those children
who continue to seize after receiving a benzodiazepine,
in view of the emerging efficacy and safety data of this
latter anticonvulsant.
Finally, we are currently involved in reviewing
the current protocol and algorithm for treating acute
tonic-clonic convulsions (including convulsive status
epilepticus) in children in the UK. This review will
identify areas where data are limited and will lead
to the design of one or more specific RCTs to address
these deficiencies. It is important to emphasize that the
original work of the UK Status Epilepticus Working
Group (1) led directly to the study by McIntyre et al.,
which was subsequently published in 2005 (2).
Richard Appleton, Stewart Macleod and Timothy
Martland.
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